Core Viewpoint - The DSA (Digital Subtraction Angiography) market in China is experiencing significant growth, driven by increasing demand for vascular imaging and intervention, with a competitive landscape featuring both foreign and domestic brands [1][9][20]. Group 1: Overview of DSA Technology - DSA machines utilize X-rays and contrast agents to visualize blood vessels, aiding in the diagnosis of various vascular diseases [2][4]. - The DSA system comprises several components, including X-ray generation, digital imaging, mechanical systems, control systems, and image processing systems [3]. Group 2: Clinical Applications - DSA is crucial for diagnosing cardiovascular diseases, brain vascular diseases, and peripheral vascular diseases, as well as for performing interventional treatments [4][6]. - It serves as the gold standard for coronary artery disease diagnosis and is essential for assessing conditions like aneurysms and vascular blockages [4][6]. Group 3: Market Size and Dynamics - In 2024, the DSA equipment bidding market in China involved 829 procurement units, with a total bid amount of approximately 8.853 billion yuan, averaging 7.484 million yuan per unit [9][11]. - The first half of 2025 saw 411 units bid, totaling around 3.168 billion yuan [9]. Group 4: Competitive Landscape - The DSA market is dominated by foreign brands such as GE Healthcare, Philips, and Siemens, which hold over 90% market share in terms of revenue [13][15]. - Domestic brands like Neusoft and United Imaging are increasingly competitive in the mid-to-low-end market and are making strides into the high-end segment [13][15]. Group 5: Regional Insights - Key regions for DSA equipment procurement include Guangdong, Zhejiang, and Sichuan, which collectively account for 28% of the total bid amount [11]. Group 6: Future Trends - The DSA market is expected to expand further due to an aging population and rising incidence of cardiovascular diseases, alongside government initiatives promoting equipment upgrades [20][22]. - Domestic brands are anticipated to gain more market share, potentially altering the current dominance of foreign brands [20][22].
研判2025!中国血管造影X射线机行业发展历程、市场现状、企业格局及未来趋势分析:外资品牌占据主导地位,国产品牌奋起直追[图]